Cellectar Biosciences Inc (CLRB)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cellectar Biosciences Inc chart...

About the Company

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p

CEO

James Caruso

Exchange

NASDAQ

Website

http://cellectar.com

$0M

Total Revenue

33

Employees

$33M

Market Capitalization

-0.84

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CLRB News

Cellectar Biosciences to Present at the 36th Annual Roth Conference

4d ago, source: Yahoo Finance

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and ...

Tierra Biosciences nabs $11 million to create new AI-guided proteins

6d ago, source:

Scientific breakthroughs have accelerated the pace at which new pharmaceuticals are being developed. Tierra Biosciences ...

IO Biotech GAAP EPS of -$0.40 misses by $0.02

on MSN ago, source:

Q4 GAAP EPS of -$0.40 misses by $0.02. Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...